Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Biogen

Tracked across 30 events · 353 articles · First seen Feb 19, 2026 · Last active Sep 23, 2026

Sentiment
17
Attention
6
Events
30
Relationships
12
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 75
Tech
Impact: Biogen announced compelling topline results from its Phase 2 CELIA study for diranersen, showing robust biomarker impact and cognitive benefit in early Alzheimer's disease, despite not meeting the primary endpoint for dose response. This positive data gives Biogen confidence to advance diranersen to registrational development.
May 14, 2026 · 7 articles
4 20
Business
Impact: Biogen is acquiring RayThera Inc. to expand its immunology pipeline and strengthen its long-term strategy in immune-mediated diseases. This acquisition adds early-stage assets and is Biogen's second major acquisition this year.
Jun 17, 2026 · 10 articles
4 -60
Regulatory
Impact: Biogen is under investigation by Pomerantz LLP for alleged securities fraud after its stock price fell following the announcement of Phase 2 CELIA study results that missed its primary endpoint.
May 21, 2026 · 21 articles
6 60
Tech
Impact: Biogen's diranersen showed promising Phase II results, slowing cognitive decline by 26% in early Alzheimer's. The company plans a Phase III trial, positioning it as a leader in tau-targeting therapies.
Jul 14, 2026 · 22 articles
4 75
Regulatory
Impact: Biogen secured reimbursement for Skyclarys in Republic of Ireland after offering a substantially improved price, expanding market access for its rare disease drug. The approval is a commercial win, though the discounted terms may affect revenue per patient.
Aug 14, 2026 · 23 articles
6 -80
Tech
Impact: Biogen produces lecanemab (Leqembi), an anti-amyloid drug whose efficacy was challenged by the Cochrane review, which could negatively affect its market performance.
Apr 16, 2026 · 6 articles
2 40
Tech
Impact: Biogen's drug Tofersen is being evaluated in the ATLAS trial for pre-symptomatic ALS, potentially expanding its market.
Jul 27, 2026 · 12 articles
2 40
Business
Impact: Biogen is a partner in Leqembi commercialization; the sales results contribute to its Q2 2026 report.
Jul 29, 2026 · 6 articles
3 20
Business
Impact: Biogen had an executive, Bharti Rai, recognized with an Ignite Leadership Award for driving enterprise-wide AI transformations within the company.
Jun 25, 2026 · 8 articles
4 50
Business
Impact: Biogen collaborates with Eisai on Leqembi development and commercialization, benefiting from the India launch through co-commercialization.
Aug 03, 2026 · 6 articles
2 30
Tech
Impact: Biogen is a member of the pre-competitive consortium that collaborated on the CNS-102 study. The results may inform its ALS and FTD clinical trial designs.
Aug 18, 2026 · 6 articles
4 55
Business
Impact: Joint development and commercialization partner for lecanemab; benefits from increased sales.
Aug 24, 2026 · 6 articles
4 50
Regulatory
Impact: Biogen is a partner in the development and commercialization of Leqembi, and the Canadian recommendation could positively affect its revenue from the drug.
Sep 01, 2026 · 6 articles
4 20
Business
Impact: Biogen is a joint development and commercialization partner for Lecanemab, participating in clinical studies. While not the primary focus of this sales forecast, it benefits from the drug's success.
May 25, 2026 · 7 articles
4 40
Business
Impact: Biogen was an early partner of Scribe, providing initial backing. While not directly involved in the IPO, the partnership highlights Scribe's early validation.
Jul 06, 2026 · 25 articles
4 50
Business
Impact: Biogen is a commercial partner for Zurzuvae, sharing revenue with Supernus; the merger may affect this partnership.
Aug 03, 2026 · 6 articles
2 10
Tech
BioArctic announced that Leqembi (lecanemab), the first therapy targeting an underlying cause of Alzheimer's disease, is now available at a private clinic in Sweden and that the first patient has started treatment. This marks the…
Impact: Biogen is a partner in the joint development and commercialization agreement for lecanemab and co-sponsors the AHEAD 3-45 study, giving it indirect exposure to the Swedish launch.
Sep 22, 2026 · 7 articles
6 10
Tech
Impact: Biogen is a funding partner for the project, supporting the research into Alzheimer s disease biomarkers.
Feb 19, 2026 · 6 articles
2 0
Business
Impact: Biogen is mentioned as McDonnell's former employer; no direct impact on Biogen.
Jul 08, 2026 · 6 articles
2 10
Tech
Impact: Greta Duréel has consulted for Biogen, but no direct impact from this study.
Aug 12, 2026 · 14 articles
4 0
Business
Impact: Biogen is mentioned as a partner in Spinraza royalties, but the trial failure has no direct impact on its existing products.
Sep 04, 2026 · 12 articles
2 5
Business
Basecamp Research, a London-based frontier AI company developing AI-designed medicines, announced an oversubscribed $140M Series C financing on September 23, 2026. The round was led by S32, with participation from Anthropic's Anthology Fund, Catalio Capital…
Impact: Mentioned only as the former employer of Basecamp's new Chief Business Officer Richard Pearce.
Sep 23, 2026 · 6 articles
4 0
Business
Impact: Biogen entered into a joint development and commercialization agreement for lecanemab with Eisai in 2014 and is involved in the AHEAD 3-45 clinical study.
May 15, 2026 · 6 articles
2 0
Business
Impact: Dr. Michelle Mellion previously held positions at Biogen, contributing to programs spanning remyelination.
May 12, 2026 · 6 articles
3 0
Business
Impact: Biogen>>> partly financed a phospho-tau vaccine program advanced by Declion Holdings LLC>>>.
May 19, 2026 · 6 articles
4 0
Business
Impact: Biogen, in collaboration with Eisai, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
1 0
Business
Impact: Patrick Vink held senior executive roles at Biogen.
Jul 08, 2026 · 6 articles
6 0
Business
Impact: Mentioned as comparison for premium paid in acquisitions.
Jul 06, 2026 · 34 articles
4 0
Regulatory
May 08, 2026 · 14 articles
2 0
Business
Apr 01, 2026 · 47 articles
ERGEN INTELLIGENCE
Track Biogen live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.